Isoquercetin

Tier C — Watch / trade

Isoquercetin

Quercis Pharma AG

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：STAT3, ACE, ALDR1

Brand：Kinisoquin

Indications (approved)：Venous thromboembolism, Pancreatic cancer, Ovarian cancer, Epithelial ovarian cancer, Sickle cell disease, COVID-19, Diabetic nephropathy, Beta thalassaemia

Regional status

Phase III

2015-01-01

Phase II

2016-11-01

China

2025-07-03

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Isoquercetin?

Approved indications include: Venous thromboembolism, Pancreatic cancer, Ovarian cancer, Epithelial ovarian cancer, Sickle cell disease, COVID-19, Diabetic nephropathy, Beta thalassaemia.

When does the Isoquercetin patent expire?

No public expiry year is available for Isoquercetin yet; this page updates once verified.

How do I get a quote for Isoquercetin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-11